Kenneth Galbraith, incoming Zymeworks CEO

January 20, 2022 07:20 AM EST

Zymeworks replaces half its C-suite, aims to lay off 25% of total workforce as new CEO takes over

Max Gelman

Senior Editor

New Zymeworks CEO Kenneth Galbraith is aiming to hit the ground running when his tenure officially begins next month, but he’ll be doing so with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

AstraZeneca details its oral SERD 'switching' regimen as feasibility questions remain

Takeda, Protagonist unveil plenary data for potential blockbuster rare blood disease drug

As life-saving checkpoint drugs move to earlier cancers, researchers debate how best to use them

Arvinas, Pfizer's PROTAC in breast cancer no better than oral SERDs

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation